In the work performed by Sugita et al. [93], monitoring of IFX levels showed a tendency towards higher IFX concentration in patients without uveitis flares (responders) and higher rates of treatment response in those with levels over 1 ug/mL (Table 2), results that are in line to those observed with ADA treatment. Here, ADA is linked to uveitis.